Aa
Entry inhibitors show promise as drugs
Entry inhibitors like REP9 AC and Myrcludex-B are promising as they are the only drugs that offer a complete CURE for Hepatitis B compared to immune modulators like Pegasys and Anti-virals like Entecavir... I think more research and concentration should be diverted to release inhibitor drugs as they seem to be promising and appropriate....
An updated progress report of the ongoing phase I/II study on the safety and efficacy of REP 9AC in patients with chronic HBV (CHB) infection is presented
AASLD 2011. An updated progress report of the ongoing phase I/II study on the safety and efficacy of REP 9AC in patients with chronic HBV (CHB) infection is presented.
METHODS: All patients were HBsAg+ with pre-treatment HBV DNA titers between 106 and 1012 copies/ml. Additionally, all patients were shown to have significant liver fibrosis as assessed by pre-treatment liver biopsy. Patients with CHB were subjected to parenteral REP 9AC therapy. Safety and virologic response (HBV DNA [Roche Cobas T], HBsAg, anti-HBs [Immunilite]) were assessed weekly at the trial site/. Off site confirmatory testing of HBsAg, HBeAg, anti-HBs, anti-HBe was conducted using the using the Architect T platform.
RESULTS: Interim data shows that 7 out of 8 patients treated to date have either cleared or have only residual levels of serum HBsAg and anti-HBsAg antibodies have been observed in all patients. Clearance of HBsAg and development of anti-HBs have been observed as early as 7 days and no later than 32 weeks. At the time of abstract submission, 6 out of 7 patients with serum HBsAg reductions had achieved a 3 to 7 log reduction in their HBV DNA titers from pre-treatment levels after 7-13 weeks of treatment. Additionally, three of these seven patients have achieved a complete control of their infection with 20-27 weeks of treatment (HBV DNA < 400cpm-, HBsAg -, HBeAg -, anti-HBs +, anti-HBe +) and are being followed off treatment. These three patients have demonstrated durable immunological control over their infections, having SVRs of 18 months, 12 months and 10.5 months after cessation of treatment.
CONCLUSIONS: These results demonstrate that REP 9AC can rapidly and effectively clear HBsAg from the serum of infected patients. This rapid HBsAg seroclearance appears to allow the restoration of an effective immune response, as evidenced by substantial reductions in serum HBV DNA, seroconversion for HBsAg and HBeAg, and the achievement of SVRs in three patients to date. These results suggest that REP 9AC may become an important new tool in the treatment of chronic hepatitis B.
AASLD 2011. An updated progress report of the ongoing phase I/II study on the safety and efficacy of REP 9AC in patients with chronic HBV (CHB) infection is presented.
METHODS: All patients were HBsAg+ with pre-treatment HBV DNA titers between 106 and 1012 copies/ml. Additionally, all patients were shown to have significant liver fibrosis as assessed by pre-treatment liver biopsy. Patients with CHB were subjected to parenteral REP 9AC therapy. Safety and virologic response (HBV DNA [Roche Cobas T], HBsAg, anti-HBs [Immunilite]) were assessed weekly at the trial site/. Off site confirmatory testing of HBsAg, HBeAg, anti-HBs, anti-HBe was conducted using the using the Architect T platform.
RESULTS: Interim data shows that 7 out of 8 patients treated to date have either cleared or have only residual levels of serum HBsAg and anti-HBsAg antibodies have been observed in all patients. Clearance of HBsAg and development of anti-HBs have been observed as early as 7 days and no later than 32 weeks. At the time of abstract submission, 6 out of 7 patients with serum HBsAg reductions had achieved a 3 to 7 log reduction in their HBV DNA titers from pre-treatment levels after 7-13 weeks of treatment. Additionally, three of these seven patients have achieved a complete control of their infection with 20-27 weeks of treatment (HBV DNA < 400cpm-, HBsAg -, HBeAg -, anti-HBs +, anti-HBe +) and are being followed off treatment. These three patients have demonstrated durable immunological control over their infections, having SVRs of 18 months, 12 months and 10.5 months after cessation of treatment.
CONCLUSIONS: These results demonstrate that REP 9AC can rapidly and effectively clear HBsAg from the serum of infected patients. This rapid HBsAg seroclearance appears to allow the restoration of an effective immune response, as evidenced by substantial reductions in serum HBV DNA, seroconversion for HBsAg and HBeAg, and the achievement of SVRs in three patients to date. These results suggest that REP 9AC may become an important new tool in the treatment of chronic hepatitis B.
Open source cancer research, Harvard, jay bradner
http://www.ted.com/talks/jay_bradner_open_source_cancer_research.html
A perhaps interesting video from ted talking about cancer research. It may apply to us as well.
1. The speaker shares a similar view that big pharmas tend to hide their innovative discovery, and make it patent safe, drug substance ready, law obeyance, and thus profitable. This is the rule of the game in pharmaceutical industry, rules, profit is the priority, saving lives is kind of a by product.
2. The speaker has demonstrated a innovate molecule that can "convince" cancel cell it is normal cell. Amazingly, It is remarkably powerful. There's a paper about it with all it's chemical component and formula and authors email address at Harvard.edu.
3. One of the examples the speaker showed is this molecule convinced fatty liver cell to become normal liver cell.
I wonder if this molecule or such model of drug discovery works on hepb, what would it be like.
http://www.ted.com/talks/jay_bradner_open_source_cancer_research.html
A perhaps interesting video from ted talking about cancer research. It may apply to us as well.
1. The speaker shares a similar view that big pharmas tend to hide their innovative discovery, and make it patent safe, drug substance ready, law obeyance, and thus profitable. This is the rule of the game in pharmaceutical industry, rules, profit is the priority, saving lives is kind of a by product.
2. The speaker has demonstrated a innovate molecule that can "convince" cancel cell it is normal cell. Amazingly, It is remarkably powerful. There's a paper about it with all it's chemical component and formula and authors email address at Harvard.edu.
3. One of the examples the speaker showed is this molecule convinced fatty liver cell to become normal liver cell.
I wonder if this molecule or such model of drug discovery works on hepb, what would it be like.
That's true. But for those who know the situation, maybe willing to donate much higher than average. If that's the case, it may not be effective to target every one, we ll have a lot of misses. Instead, we could target to those who are willing to donate a lot more.
Guess long tail theory applies here too. 20% of the donors are going to contribute 80% of all the donations.
Guess long tail theory applies here too. 20% of the donors are going to contribute 80% of all the donations.
One thing we are not considering is that out of those let's say 400 000 000 supposedly infected, just a little part are aware of the fact, and of those who know another small part is informed about the real size of the problem. If I, for example, had not donated blood, I would have never known that I have it. And yet I was told by doctors that I am OK, and went on like this for another 12 years, before I came upon more info on the web. According to an article on the subject, "About 5.3 million people in the US are estimated to have chronic Hepatitis B or C and there are estimates there are only about 10 percent of these individuals even know they're infected,"
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
